One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis

Psychiatry Research

Volumn 200, Issue 2-3, 2012, Pages 693-701

  San, Luis ^a   Arranz, Belen ^b   Perez, Victor ^c   Safont, Gemma ^d   Corripio, Iluminada ^c   Ramirez, Nicolas ^e   Dueñas, Rosa ^b   Alvarez, Enric ^c  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e HOSPITAL SAN RAFAEL   (Spain)

Author keywords

Discontinuation; First episode psychosis; Second generation antipsychotics

Indexed keywords

CITALOPRAM; FLUOXETINE; HALOPERIDOL; LITHIUM; MIRTAZAPINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; VENLAFAXINE; ZIPRASIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; BRIEF PSYCHOTIC DISORDER; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROLOGIC DISEASE; OPEN STUDY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SUBSTANCE INDUCED PSYCHOSIS; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; PIPERAZINES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 84872416058     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.07.005     Document Type: Article

References (57)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophrenia Research 1990, 3:247-251.
2. Arranz B., Rosel P., San L., Ramírez N., Dueñas R.M., Salavert J., Centeno M., del Moral E. Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients. Psychiatry Research 2007, 153:103-109.
3. Beasley C.M., Stauffer V.L., Liu-Seifert H., Taylor C.C., Dunayevich E., Davis J.M. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics. An integrated analysis. Journal of Clinical Psychopharmacology 2007, 27:252-258.
4. Buckley P.F., Correll C.U., Miller A.L. First-episode psychosis: a window of opportunity for best practices. CNS Spectrum 2007, 12(915):1-12.
5. Cannon-Spoor H.E., Potkin S.G., Wyatt R.J. Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 1982, 8:470-484.
6. Crespo-Facorro B., Pérez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Llorca J., Vazquez-Barquero J.L. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. Journal of Clinical Psychiatry 2006, 67:1511-1521.
7. Crespo-Facorro B., Perez-Iglesias R., Mata I., Martinez-Garcia O., Ortiz V., Pelayo-Teran J.M., Valdizan E., Vazquez-Barquero J.L. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. Journal of Psychopharmacology 2011, 25:744-754.
8. Dunayevich E., Ascher-Svanum H., Zhao F., Jacobson J.G., Phillips G.A., Dellva M.A., Green A.I. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. Journal of Clinical Psychiatry 2007, 64:1163-1171.
9. Emsley R.A. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophrenia Bulletin 1999, 25:721-729.
10. Fleischhacker W.W., Keet I.P., Kahn R.S. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophrenia Research 2005, 78:147-156.
11. Fleischhacker W.W., Derks E., Kahn R.S. Interpreting treatment trials in schizophrenia patients: lessons learned from EUFEST. Schizophrenia Research 2012, 138:39-40.
12. Gaebel W., Riesbeck M., Wölwer W., Klimke A., Eickhoff M., von Wilmsdorff M., Lemke M., Heuser I., Maier W., Huff W., Schmitt A., Sauer H., Riedel M., Klingberg S., Köpcke W., Ohmann C., Möller H.J. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. Journal of Clinical Psychiatry 2011, 72(2):205-218.
13. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 2000, 321:1371-1376.
14. Green A.I., Lieberman J.A., Hamer R.M., Glick I.D., Gur R.E., Kahn R.S., McEvoy J.P., Perkins D.O., Rothschild A.J., Sharma T., Tohen M.F., Woolson S., Zipursky R.B. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophrenia Research 2006, 86:234-243.
15. Hatta K., Sato K., Hamakawa H., Takebayashi H., Kimura N., Ochi S., Sudo Y., Asukai N., Nakamura H., Usui C., Kawabata T., Hirata T., Sawa Y. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Research 2009, 113:49-55.
16. Haro J.M., Novick D., Suarez D., Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: a 36-month results from the SOHO study. Journal of Psychiatry Research 2009, 43(3):265-273.
17. Hofer A., Hummer M., Huber R., Kurzm M., Walcht T., Fleischhacker W.W. Selection bias in clinical trials with antipsychotics. Journal of Clinical. Psychopharmacology 2000, 20:699-702.
18. Jakovljević M. New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence. Psychiatria Danubina 2009, 21(4):446-452.
19. Johnsen E., Jørgensen H.A. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC. Psychiatry. 2008, 8:31.
20. Johnsen E., Kroken R.A., Wentzel-Larsen T., Jorgensen H.A. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone and ziprasidone. BMC Psychiatry 2010, 10:26.
21. Kahn R., Fleischhacker W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
22. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardization. British Journal of Psychiatry 1989, 7:59-67.
23. Kelly D.L., Conley R.R., Carpenter W.T. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005, 65:1113-1138.
24. Lambert M., Conus P., Lambert T., McGorry P.D. Pharmacotherapy of first-episode psychosis. Expert Opinion in Pharmacotherapy 2003, 4:1-34.
25. Lane H.Y., Chang W.H., Chiu C.C., Huang M.C., Lee S.H., Chen J.Y. A pilot double-blind dose-comparison study of risperidone in drug-naïve, first-episode schizophrenia. Journal of Clinical Psychiatry 2001, 62:994-995.
26. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, 2nd edn. American Journal of Psychiatry 2004, 161:1-56.
27. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999, 35:51-68.
28. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003, 361:1581-1589.
29. Leucht S., Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. Journal of Clinical Psychiatry 2006, 67(5):3-8.
30. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
31. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 2003, 160:1396-1404.
32. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-23.
33. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987, 334:1-100.
34. March J.S., Silva S.G., Compton S., Shapiro M., Califf R., Krishnan R. The case for practical clinical trials in psychiatry. American Journal of Psychiatry 2005, 162:836-846.
35. Martin J.L., Perez V., Sacristán M., Rodríguez-Artalejo F., Martínez C., Alvarez E. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry 2006, 21:11-20.
36. McEvoy J.P., Lieberman J.A., Perkins D.O., Hamer R.M., Gu H., Lazarus A., Sweitzer D., Olexy C., Weiden P., Strakowski S.D. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 2007, 164:1050-1060.
37. Merlo M.C., Hofer H., Gekle W., Berger G., Ventura J., Panhuber I., Latour G., Marder S.R. Risperidone, 2mg/day vs. 4mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. Journal of Clinical Psychiatry 2002, 63:885-891.
38. Miller B.J. A review of second-generation antipsychotic discontinuation. Journal of Psychiatric Practice 2008, 14:289-300.
39. Mojtabai R., Lavelle J., Gibson P.J., Sohler N.L., Craig T.J., Carlson G.A., Bromet E.J. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatric Services 2002, 53:337-339.
40. Möller H.J., Riedel M., Jäger M., Wickelmaier F., Maier W., Kühn K.U., Buchkremer G., Heuser I., Klosterkötter J., Gastpar M., Braus D.F., Schlösser R., Schneider F., Ohmann C., Riesbeck M., Gaebel W. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within German Research Network on Schizophrenia. Internal Journal of Neuropsychopharmacology 2008, 11(7):985-997.
41. Norman R., Malla A.K. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychological Medicine 2001, 31:381-400.
42. Perez-Iglesias R., Crespo-Facorro B., Martinez-Garcia O., Ramirez-Bonilla M.L., Alvarez-Jimenez M., Pelayo-Teran J.M., Garcia-Unzueta M.T., Amado J.A., Vazquez-Barquero J.L. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophrenia Research 2008, 99:13-22.
43. Perez-Iglesias R., Mata I., Pelayo-Teran J.M., Amado J.A., Garcia-Unzueta M.T., Berja A., Martinez-Garcia O., Vazquez-Barquero J.L., Crespo-Facorro B. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population. Schizophrenia Research 2009, 107:115-121.
44. Perkins D.O., Gu H., Weiden P.J., McEvoy J.P., Hamer R.M., Lieberman J.A. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized. Double-blind, flexible-dose, multicenter study. Journal of Clinical Psychiatry 2008, 69:106-113.
45. Rabinowitz J., Bromet E., Davidson M. Are patients enrolled in first episode psychosis drug trials representative of those treated in routine clinical practice?. Schizophrenia Research 2003, 61:149-155.
46. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research 2002, 57:209-221.
47. Robinson D.G., Woerner M.G., Delman H.M., Kane J.M. Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin 2005, 31(3):705-722.
48. Robinson D.G., Woerner M.G., Napolitano B., Patel R.C., Sevy S.M., Gunduz-Bruce H., Soto-Perello J.M., Mendelowitz A., Khadivi A., Miller R., McCormack J., Lorell B.S., Lesser M,L., Schooler N.R., Kane J.M. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. American Journal of Psychiatry 2006, 163:2096-2102.
49. Rummel C., Hamann J., Kissling W., Leucht S. New generation antipsychotics for first episode schizophrenia. Cochrane Database Systematic Reviews 2003, 4.
50. Salimi K., Jarskog L.F., Lieberman J.A. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 2009, 23(10):837-855.
51. Sanger T.M., Lieberman J.A., Tohen M., Grundy S., Beasley C., Tollefson G.D. Olanzapine versus haloperidol treatment in first-episode psychosis. American Journal of Psychiatry 1999, 156:79-87.
52. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., McGorry P.D., Van Hove I., Eerdekens M., Swyzen W., De Smedt G. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. American Journal of Psychiatry 2005, 162:947-953.
53. Shrivastava A., Johnston M., Shah N., Bureau Y. Redefining outcome measures in schizophrenia: integrating social and clinical parameters. Current Opinion in Psychiatry 2010, 23:120-126.
54. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970, 212:11-19.
55. Spitzer R.L., Williams J., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID).I: history, rationale, and description. Archives of General Psychiatry 1992, 49:624-629.
56. Stroup T.S., Alves W.M., Hamer R.M., Lieberman J.A. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Reviews Drug Discovery 2006, 5:133-146.
57. Taylor M., Cavanagh J., Hogson R., Tiihonen J. Examining the effectiveness of antipsychotic medication in first-episode psychosis. Journal of Psychopharmacology 2012, 26:27-32.